Manipulating the body's endocannabinoid receptor may result in neuropsychiatric issues

Published Date: 24 Sep 2025

Endocannabinoids are similar to the cannabinoids present in cannabis, but they are found naturally in the body. Endocannabinoids—and cannabinoids—work through a signaling system that supports neurodevelopment, but whether ...

Read Full News

Latest News

What The FDA Psychedelic Hearing Means for Psychiatrists

TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know Andrew Leuchter, MD, Scott A. Wilke, MD, PhD, Linda Carpenter, MD

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD John Sonnenberg, PhD

John Sonnenberg, PhD, reflects on Emerge phase 3 topline data for DT120 in MDD, including MADRS outcomes, remission rates, and what comes next.

Q2 2026 Recap: Psychiatry News & Updates Chelsie Derman

Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.

3 Psychiatry Headlines You Missed in June 2026 Chelsie Derman

From an ADHD therapy's regulatory setback to a psychedelic's rapid MDD response and TMS's move into patients' homes, here are 3 psychiatry stories from June 2026 you may have missed.

First Half 2026 Recap – Psychiatry Chelsie Derman

First half 2026 psychiatry recap: Lumateperone and milsaperidone approvals, ProlivRx for MDD, centanafadine for ADHD, and 3 psychedelic trials.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

Findings from the phase 3 TransportNPC study showed that Trappsol Cyclo missed the primary end point in Niemann-Pick type C, but subgroup and survival data support planned 2026 NDA.

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.

Latest News

What The FDA Psychedelic Hearing Means for Psychiatrists

New accelerated TMS protocols and an FDA-approved at-home device are changing how psychiatrists treat MDD after antidepressant failure.

John Sonnenberg, PhD, reflects on Emerge phase 3 topline data for DT120 in MDD, including MADRS outcomes, remission rates, and what comes next.

Q2 2026 psychiatry recap: Lumateperone expands for schizophrenia relapse, DT120 shows phase 3 promise in MDD, and 3 TMS advances for depression care.

From an ADHD therapy's regulatory setback to a psychedelic's rapid MDD response and TMS's move into patients' homes, here are 3 psychiatry stories from June 2026 you may have missed.

First half 2026 psychiatry recap: Lumateperone and milsaperidone approvals, ProlivRx for MDD, centanafadine for ADHD, and 3 psychedelic trials.

News All Time

Metabolic Traits Differentiate AERS+, AERS− MDD Subtypes, With Arvid Harder Arvid Harder

New genome-wide data show AERS+ and AERS− subtypes of major depressive disorder diverge in heritability and metabolic genetic correlations.

Voyage: DT120 ODT Reduces Anxiety in Phase 3 GAD Trial Chelsie Derman

DT120 ODT produced a 5.4-point placebo-adjusted HAM-A reduction at week 12 in the phase 3 Voyage trial for generalized anxiety disorder.

AERS Subtypes Show Distinct Genetic Architecture in MDD Arvid Harder

A genome-wide study of > 460,000 individuals identify 27 loci separating AERS+ and AERS− subtypes of major depressive disorder by metabolic profile.

MDMA-Assisted Therapy NDA Resubmitted to FDA for PTSD Chelsie Derman

Resilient Pharmaceuticals has resubmitted its MDMA-assisted therapy NDA for PTSD without a new phase 3 trial, MAPS reported.

HTTP error: 503HTTP error: 503

DT120 ODT Receives Second FDA Breakthrough Therapy Designation in MDD Chelsie Derman

The FDA granted DT120 (lysergide) ODT Breakthrough Therapy designation for MDD, citing promising phase 3 Emerge data.

Do More TMS Pulses Track with Better Depression Outcomes? Jonathan Downar, MD, PhD

A new meta-analysis found total pulse count predicted outcomes in a roughly linear pattern across sham-controlled trials of accelerated rTMS.

HTTP error: 503HTTP error: 503

ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD

HTTP error: 503HTTP error: 503HTTP error: 503HTTP error: 503HTTP error: 503

Manipulating the body's endocannabinoid receptor may result in neuropsychiatric issues

Latest News

What The FDA Psychedelic Hearing Means for Psychiatrists

TMS for MDD Is Changing Fast. Here's What Psychiatrists Need to Know Andrew Leuchter, MD, Scott A. Wilke, MD, PhD, Linda Carpenter, MD

Emerge Phase 3: DT120 Shows Rapid, Durable Relief in MDD John Sonnenberg, PhD

Q2 2026 Recap: Psychiatry News & Updates Chelsie Derman

3 Psychiatry Headlines You Missed in June 2026 Chelsie Derman

First Half 2026 Recap – Psychiatry Chelsie Derman

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Todays Updates

Trappsol Cyclo Misses Primary End Point in Phase 3 Trial for Niemann-Pick Disease Type C Isabella Ciccone, MPH

NeurologyLive® Friday 5 — October 2, 2026 Isabella Ciccone, MPH

Latest News

News All Time

Metabolic Traits Differentiate AERS+, AERS− MDD Subtypes, With Arvid Harder Arvid Harder

Voyage: DT120 ODT Reduces Anxiety in Phase 3 GAD Trial Chelsie Derman

AERS Subtypes Show Distinct Genetic Architecture in MDD Arvid Harder

MDMA-Assisted Therapy NDA Resubmitted to FDA for PTSD Chelsie Derman

DT120 ODT Receives Second FDA Breakthrough Therapy Designation in MDD Chelsie Derman

Do More TMS Pulses Track with Better Depression Outcomes? Jonathan Downar, MD, PhD

ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD

Recommended News For You

In Sickle Cell Disease, Lovo-Cel is "Life-Changing, Transformative.".

Immunotherapy Remains Little Used in Head and Neck Cancer

In cancer patients taking immune checkpoint inhibitors, systematic vitamin D supplementation improves outcomes.

New Gene Therapy Nears EU Nod for Bladder Cancer

An Examine More Into the Acceptance of CRISPR/Cas9 Gene Therapy for Sickle Cell Illness.

Radiotherapy after mastectomy can be avoided, study finds

Low-Dose Radiation Provides Almost Perfect Control Over Slow-Growing Lymphoma.

Recommended Articles For You

Unlocking the Secrets of Improved Ovarian Cancer Survival Rates

Navigating the Challenges of Vaso-Occlusive Crisis: A Guide for Patients and Caregivers

An Overview Of Daunorubicin: What Is It Used For And How Does It Work?

Magnetically Controlled Surgical Microdevices for Targeted Hematologic Tissue Intervention

Whats more on Hidoc Dr.

Medical Updates

KOL Videos

Surveys

Events

Featured News

Featured Articles

Featured Events

Featured KOL Videos

Quick Links

Verification

Welcome to Hidoc Dr.